Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001641172-25-007899
Filing Date
2025-04-30
Accepted
2025-04-30 17:23:41
Documents
18
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A form10-ka.htm   iXBRL 10-K/A 395964
2 EX-31.1 ex31-1.htm EX-31.1 18768
3 GRAPHIC form10-ka_001.jpg GRAPHIC 113534
4 GRAPHIC form10-ka_002.jpg GRAPHIC 109705
  Complete submission text file 0001641172-25-007899.txt   1409979

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE prph-20241231.xsd EX-101.SCH 3428
6 XBRL DEFINITION FILE prph-20241231_def.xml EX-101.DEF 5351
7 XBRL LABEL FILE prph-20241231_lab.xml EX-101.LAB 84439
8 XBRL PRESENTATION FILE prph-20241231_pre.xml EX-101.PRE 62473
20 EXTRACTED XBRL INSTANCE DOCUMENT form10-ka_htm.xml XML 9839
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 000-21617 | Film No.: 25897595
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)